[go: up one dir, main page]

WO2011048554A3 - Association d'un lysat de probiotique et d'un derive c-glycoside - Google Patents

Association d'un lysat de probiotique et d'un derive c-glycoside Download PDF

Info

Publication number
WO2011048554A3
WO2011048554A3 PCT/IB2010/054744 IB2010054744W WO2011048554A3 WO 2011048554 A3 WO2011048554 A3 WO 2011048554A3 IB 2010054744 W IB2010054744 W IB 2010054744W WO 2011048554 A3 WO2011048554 A3 WO 2011048554A3
Authority
WO
WIPO (PCT)
Prior art keywords
combination
glycoside derivative
lysate
probiotic lysate
probiotic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2010/054744
Other languages
English (en)
Other versions
WO2011048554A2 (fr
Inventor
Lionel Breton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LOreal SA
Original Assignee
LOreal SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LOreal SA filed Critical LOreal SA
Publication of WO2011048554A2 publication Critical patent/WO2011048554A2/fr
Publication of WO2011048554A3 publication Critical patent/WO2011048554A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A61K8/602—Glycosides, e.g. rutin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
    • C07H3/02—Monosaccharides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Birds (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)

Abstract

La présente invention concerne l'utilisation cosmétique d'une association comprenant un lysat d'au moins un microorganisme probiotique du genre Bifidobacterium sp. avec au moins un dérivé C-glycoside à titre d'actif utile pour le soin cosmétique des matières kératiniques.
PCT/IB2010/054744 2009-10-21 2010-10-20 Association d'un lysat de probiotique et d'un derive c-glycoside Ceased WO2011048554A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
FR0957374 2009-10-21
FR0957374A FR2951377B1 (fr) 2009-10-21 2009-10-21 Association d'un lysat de probiotique et d'un derive c-glycoside
US27278809P 2009-11-03 2009-11-03
US61/272,788 2009-11-03

Publications (2)

Publication Number Publication Date
WO2011048554A2 WO2011048554A2 (fr) 2011-04-28
WO2011048554A3 true WO2011048554A3 (fr) 2011-06-23

Family

ID=42244536

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2010/054744 Ceased WO2011048554A2 (fr) 2009-10-21 2010-10-20 Association d'un lysat de probiotique et d'un derive c-glycoside

Country Status (2)

Country Link
FR (1) FR2951377B1 (fr)
WO (1) WO2011048554A2 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013109635A1 (fr) * 2012-01-16 2013-07-25 Elizabeth Mckenna Compositions et méthodes utilisées pour traiter des maladies et des troubles hépatiques
US12268718B2 (en) 2012-01-16 2025-04-08 Labyrinth Holdings Llc Control of cellular redox levels
WO2013122931A2 (fr) 2012-02-14 2013-08-22 The Procter & Gamble Company Utilisation topique d'un agent prébiotique commensal dermique et compositions le contenant
EP2898073A4 (fr) 2012-09-21 2016-03-23 Elizabeth Mckenna Compositions à base d'oligonucléotides cpg naturels et leurs utilisations thérapeutiques
JP2019511505A (ja) 2016-03-31 2019-04-25 ゴジョ・インダストリーズ・インコーポレイテッド 抗菌ペプチド刺激性清浄組成物
JP2019510037A (ja) 2016-03-31 2019-04-11 ゴジョ・インダストリーズ・インコーポレイテッド 抗菌ペプチド刺激性洗浄組成物
US10874700B2 (en) 2016-03-31 2020-12-29 Gojo Industries, Inc. Sanitizer composition with probiotic/prebiotic active ingredient
FR3055799B1 (fr) 2016-09-15 2020-06-19 Basf Beauty Care Solutions France Sas Nouvelle utilisation cosmetique et/ou nutraceutique ou dermatologique d'un extrait de levure
WO2018098152A1 (fr) 2016-11-23 2018-05-31 Gojo Industries, Inc. Composition désinfectante comprenant une substance active probiotique/prébiotique
FR3097441B1 (fr) * 2019-06-24 2021-06-25 Oreal Composition cosmétique comprenant un lysat deBifidobacterium species, un extrait de levure du genreSaccharomyces, et un monosaccharide mannose et ses utilisations cosmétiques

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4464362A (en) * 1980-06-27 1984-08-07 Estee Lauder Inc. Topical skin repair composition
WO2002028402A1 (fr) * 2000-10-06 2002-04-11 Société des Produits Nestlé S.A. Utilisation de bacteries lactiques probiotiques afin d'equilibrer le systeme immunitaire de la peau
FR2886297A1 (fr) * 2005-05-30 2006-12-01 Oreal Composes c-glycosides et leur utilisation pur depigmenter la peau
FR2899588A1 (fr) * 2006-04-07 2007-10-12 Oreal Utilisation de compose c-glycoside derive de galactose comme agent activateur et regulateur de l'immunite cutanee
WO2007116012A1 (fr) * 2006-04-07 2007-10-18 L'oréal Utilisation d'un composé c-glycoside dérivé du l-fucose et du d-fucose en tant qu'agent pour activer et réguler l'immunité cutanée
EP2033627A2 (fr) * 2007-09-04 2009-03-11 L'oreal Utilisation d'un lysat de Bifidobacterium species pour le traitement de peaux sensibles
WO2009053564A2 (fr) * 2007-09-04 2009-04-30 L'oreal Utilisation cosmetique de lysat de bifidobacterium species pour renforcer la fonction barriere cutanee

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5658880A (en) 1993-06-16 1997-08-19 Glycomed Incorporated Sialic acid/fucose based medicaments
US5508387A (en) 1993-08-04 1996-04-16 Glycomed Incorporated Selectin binding glycopeptides
US5614615A (en) 1995-03-21 1997-03-25 The Scripps Research Institute Sialyl Lewis X mimetics incorporating fucopeptides
FR2818547B1 (fr) 2000-12-22 2006-11-17 Oreal Nouveaux derives c-glycosides et utilisation
JP2005533057A (ja) 2002-06-13 2005-11-04 ニューヨーク・ユニバーシティ 合成ｃ−糖脂質、ならびに癌、感染性疾患および自己免疫疾患を処置するための合成ｃ−糖脂質の使用

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4464362A (en) * 1980-06-27 1984-08-07 Estee Lauder Inc. Topical skin repair composition
WO2002028402A1 (fr) * 2000-10-06 2002-04-11 Société des Produits Nestlé S.A. Utilisation de bacteries lactiques probiotiques afin d'equilibrer le systeme immunitaire de la peau
FR2886297A1 (fr) * 2005-05-30 2006-12-01 Oreal Composes c-glycosides et leur utilisation pur depigmenter la peau
FR2899588A1 (fr) * 2006-04-07 2007-10-12 Oreal Utilisation de compose c-glycoside derive de galactose comme agent activateur et regulateur de l'immunite cutanee
WO2007116012A1 (fr) * 2006-04-07 2007-10-18 L'oréal Utilisation d'un composé c-glycoside dérivé du l-fucose et du d-fucose en tant qu'agent pour activer et réguler l'immunité cutanée
EP2033627A2 (fr) * 2007-09-04 2009-03-11 L'oreal Utilisation d'un lysat de Bifidobacterium species pour le traitement de peaux sensibles
WO2009053564A2 (fr) * 2007-09-04 2009-04-30 L'oreal Utilisation cosmetique de lysat de bifidobacterium species pour renforcer la fonction barriere cutanee

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CAVEZZA A ET AL: "Synthesis of Pro-Xylane<TM>: A new biologically active C-glycoside in aqueous media", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, ELSEVIER SCIENCE, GB, vol. 19, no. 3, 1 February 2009 (2009-02-01), pages 845 - 849, XP025925835, ISSN: 0960-894X, [retrieved on 20081213], DOI: DOI:10.1016/J.BMCL.2008.12.037 *

Also Published As

Publication number Publication date
WO2011048554A2 (fr) 2011-04-28
FR2951377B1 (fr) 2012-06-22
FR2951377A1 (fr) 2011-04-22

Similar Documents

Publication Publication Date Title
WO2011048554A3 (fr) Association d&#39;un lysat de probiotique et d&#39;un derive c-glycoside
BR112012013722A2 (pt) uso cosmético de pelo menos um microorganismo probiótico, especialmente do gênero lactobacillus sp.e processo cosmético.
CL2012000869A1 (es) Composicion que comprende cepa seleccionada de lactobacillus plantarum cect 7527, o cepas mutantes de la misma; uso de una composicion para prevenir y/o tratar transtornos cardiovasculares.
WO2010000877A3 (fr) Formulation à base de bisabolol et de [6]-paradol produisant un effet apaisant sur les irritations
WO2011073437A3 (fr) Compositions cosmétiques ou dermatologiques à base de bactériocines et de prébiotiques
WO2009074735A8 (fr) Utilisation d&#39;un nouvel agent naturel dans des compositions cosmetiques
IN2012DN01638A (fr)
WO2012030984A3 (fr) Compositions pour la peau et leurs applications
WO2014018596A3 (fr) Alpha (1,2) fucosyltransférases appropriées pour une utilisation dans la production d&#39;oligosaccharides fucosylés
MX2010002247A (es) Uso de una combinacion de hesperidina y de un microorganismo para influir en la funcion de barrera de la piel.
MX376284B (es) Una composición que comprende un agente antibiótico y un agente dispersante o un agente antiadhesivo.
MY165086A (en) Formulations of rifaximin and uses thereof
WO2011093833A3 (fr) Formulations effervescentes contenant de la céphalosporine de deuxième génération
WO2009056550A3 (fr) Bromhydrate de bupropione et ses applications thérapeutiques
PL2364712T3 (pl) Miejscowa kompozycja kosmetyczna lub farmaceutyczna zawierająca probiotyczne szczepy pałeczek bakterii kwasu mlekowego i jej stosowanie
WO2008085221A3 (fr) Utilisation thérapeutique de cellules exprimant cd31
BR112012013720A2 (pt) uso cosmético de pelo menos um microorganismo probiótico, especialmente do gênero lactobacillus sp.e processo cosmético.
MX2010000422A (es) Combinacion cosmetica de un microorganismo y de un derivado de fitosfigosina.
WO2009093104A3 (fr) Utilisation d&#39;huile d&#39;olive transestérifiée dans le domaine cosmétique
WO2010021607A3 (fr) Préparation pharmaceutique
WO2010147830A3 (fr) Modulateurs aminothiazole de bêta-3-adrénorécepteur
TW200942530A (en) Pyridine compounds
WO2011042902A3 (fr) Microcapsules comprenant du peroxyde de benzoyle et compositions topiques comprenant celles-ci
GEP201606589B (en) Novel bacterium and extracts of said bacterium and the use of same in dermatology
WO2010046061A3 (fr) Préparations cosmétiques et/ou pharmaceutiques

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10776170

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10776170

Country of ref document: EP

Kind code of ref document: A2